Table 1.
Healthcare use, unadjusted costs (€, year 2010 values) and quality-adjusted life-years accrued over 2 years in the study population (ANRS 140 DREAM trial, n = 189)
| Variables | cART (n = 94) | MT (n = 95) | p valuea |
|---|---|---|---|
| Inpatient care | |||
| Number of inpatient admissions | 0.1 ± 0.4 | 0.2 ± 0.5 | 0.26 |
| Cost per patient | 499.3 ± 1475.3 | 757.9 ± 1967.6 | 0.47 |
| Doctors’ outpatient consultations | |||
| Number of consultations | 10.1 ± 1.9 | 10.0 ± 1.9 | 0.21 |
| Cost per patient | 251.7 ± 46.8 | 248.7 ± 45.4 | 0.62 |
| Biological tests | |||
| Number of all laboratory tests | 286.3 ± 56.0 | 282.5 ± 52.4 | 0.12 |
| Cost per patient | 2410.3 ± 463.1 | 2380.1 ± 433.5 | 0.31 |
| Antiretroviral drugs | |||
| Number of days on LPV/r | 21.4 ± 95.9 | 615.4 ± 280.1 | < 0.001 |
| Number of days on EFV/FTC/TDF | 582.8 ± 253.3 | 41.6 ± 147.6 | < 0.001 |
| Cost per patient | 16,472.6 ± 4734.0 | 12,680.2 ± 5143.0 | < 0.001 |
| Drugs for opportunistic infections | |||
| Number of drugs | 12.8 ± 13.1 | 12.8 ± 13.9 | 0.48 |
| Cost per patient | 1025.0 ± 1809.4 | 1532.6 ± 3206.5 | 0.38 |
| Work stoppages | |||
| Number of days | 9.0 ± 27.2 | 6.7 ± 25.2 | 0.35 |
| Cost per patient | 474.6 ± 1822.3 | 286.5 ± 1288.8 | 0.69 |
| Total cost | |||
| Cost per patient | 21,133.5 ± 6389.8 | 17,886.0 ± 7130.6 | < 0.001 |
| Total direct medical costb | |||
| Cost per patient | 20,658.9 ± 6036.1 | 17,599.5 ± 6898.1 | < 0.001 |
| QALYs | |||
| QALYs per patient | 1.4163 ± 0.21 | 1.4275 ± 0.21 | 0.75 |
Data are presented as mean ± standard deviation unless otherwise indicated
cART combination antiretroviral therapy, EFV/FTC/TDF efavirenz/emtricitabine/tenofovir, LPV/r lopinavir/ritonavir, MT monotherapy, QALY quality-adjusted life-years
aChi squared test for categorical variables; Wilcoxon rank-sum test for continuous variables
bTotal direct medical costs correspond to all costs excluding costs related to work stoppage